Enlivex Therapeutics Ltd

Add to watchlist
€7.95
Last updated:06/10/2021
1BT: F
Enlivex Therapeutics Ltd

Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. It is developing Allocetra, an off-the-shelf cell therapy designed to reprogram macrophages into homeostatic state. Resetting non-homeostatic macrophages into homeostatic state is critical for immune system… Show more

P/E ratio
-
vs. 0.00x forward

Company has negative earnings per share so P/E ratio is not available.

Stock volatility (Beta)
past 12 months

Become our supporter to unlock all data!
Company results
Quarterly
Annual
Fundamentals
2017
2018
2019
2020
Net Income
Income minus expenses, depreciation, interest, taxes, and other expenses
-2.504M
-4.242M
-69.41%
-9.384M
-121.22%
-11.824M
-26.00%
Cashflow
Sum up money going in and out company
-2.304M
-3.161M
-37.20%
-7.041M
-122.75%
-11.007M
-56.33%
Total liabilities
All combined debts and obligations
460K
1.328M
+188.70%
6.278M
+372.74%
-
Company profile
CEO
Mr. Shai Novik M.B.A.
Market capitalization
Micro (152.59M)